FTC Asks To Restrict Pay-For-Delay Deals To Lower Consumers’ Health Care Costs
The Federal Trade Commission (FTC) has released a report of data pertaining to the 2011 fiscal year which showed that pharmaceutical companies continued an anticompetitive trend of paying potential generic rivals to delay the introduction of low-cost prescription drug alternatives for American consumers. If you’re like me, generic pharmaceutical drugs save my life, not only …
